Icure Pharmaceutical (XKRX:175250) Risk Assessment

View and export this data going back to 2018. Start your Free Trial

What is Icure Pharmaceutical Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Icure Pharmaceutical is: High Risk: High uncertainty with risk-return tradeoff.

Competitive Comparison of Icure Pharmaceutical's Risk Assessment

For the Drug Manufacturers - Specialty & Generic subindustry, Icure Pharmaceutical's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Icure Pharmaceutical's Risk Assessment Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Icure Pharmaceutical's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Icure Pharmaceutical's Risk Assessment falls into.

Icure Pharmaceutical (XKRX:175250) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Icure Pharmaceutical Risk Assessment Related Terms

Thank you for viewing the detailed overview of Icure Pharmaceutical's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Icure Pharmaceutical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Icure Pharmaceutical Inc (XKRX:175250) » Definitions » Risk Assessment

Traded in Other Exchanges

N/A

Address

7, Saimdang-ro 1-gil, Seocho-gu, Seoul, KOR

Website

https://www.icure.co.kr

Icure Pharmaceutical Inc operates as a biopharmaceutical company engages in the development and commercialization of novel transdermal drug delivery formulation. It also developed and commercialized various patches and hydrogels for the treatment of rheumatic arthritis pain, nicotine replacement therapy, medicated wound dressings, skin care, and dental care. The products pipeline is also aimed at the development of prescription drugs to diseases of the central nervous system, asthma, and pain.

Icure Pharmaceutical Headlines

No Headlines